Curis Inc. (NASDAQ: CRIS) reported fourth quarter 2025 financial results and provided updates on its emavusertib clinical trials. The biotechnology company posted net income of $19.4 million for the quarter, compared to a net loss of $9.6 million in the same period of 2024.

For the full year 2025, Curis reported a net loss of $7.6 million, or $0.58 per share, compared to a net loss of $43.4 million, or $6.88 per share, in 2024. The improved results were driven by a $27.2 million gain from the sale of its Erivedge royalty assets.

The company presented clinical data for emavusertib, its IRAK4 and FLT3 inhibitor, at medical conferences. In primary central nervous system lymphoma (PCNSL), results showed 100% objective response rate in five BTK inhibitor-naive patients and 37% response rate in 19 BTK inhibitor-experienced patients when emavusertib was combined with ibrutinib.

In acute myeloid leukemia, preliminary data from 10 patients showed that 5 of 8 evaluable patients achieved minimal residual disease conversion when emavusertib was added to azacitidine and venetoclax therapy.

Curis initiated a Phase 2 study of emavusertib combined with zanubrutinib in chronic lymphocytic leukemia patients. The company received orphan drug designation from the FDA and European Commission for emavusertib in PCNSL treatment.

In January 2026, Curis completed a private placement raising $20.2 million initially, with potential additional proceeds of up to $60.6 million through warrant exercises. As of December 31, 2025, the company held $5.1 million in cash and cash equivalents.

Research and development expenses decreased to $28.3 million in 2025 from $38.6 million in 2024. The company projects its current cash resources and recent financing should fund operations into the second half of 2027.